



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/653,794	09/01/2000	Meir S. Sacks	286262-00005	5973

7590 12/19/2001

Diane R Meyers
Eckert Seamans Cherin & Mellott LLC
600 Grant Street 44th Floor
Pittsburgh, PA 15219

[REDACTED] EXAMINER

KISHORE, GOLLAMUDI S

[REDACTED] ART UNIT [REDACTED] PAPER NUMBER

1615

DATE MAILED: 12/19/2001

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary

Application No. 09/653,794	Applicant(s) Sacks
Examiner Gollamudi S. Kishore, Ph.D	Art Unit 1615



-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE three MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136 (a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).
- Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

1) Responsive to communication(s) filed on Nov 26, 2001.

2a) This action is FINAL. 2b) This action is non-final.

3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11; 453 O.G. 213.

Disposition of Claims

4) Claim(s) 1-32 is/are pending in the application.

4a) Of the above, claim(s) 26-32 is/are withdrawn from consideration.

5) Claim(s) _____ is/are allowed.

6) Claim(s) 1-25 is/are rejected.

7) Claim(s) _____ is/are objected to.

8) Claims _____ are subject to restriction and/or election requirement.

Application Papers

9) The specification is objected to by the Examiner.

10) The drawing(s) filed on _____ is/are objected to by the Examiner.

11) The proposed drawing correction filed on _____ is: a) approved b) disapproved.

12) The oath or declaration is objected to by the Examiner.

Priority under 35 U.S.C. § 119

13) Acknowledgement is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d).

a) All b) Some* c) None of:

1. Certified copies of the priority documents have been received.
2. Certified copies of the priority documents have been received in Application No. _____.
3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

*See the attached detailed Office action for a list of the certified copies not received.

14) Acknowledgement is made of a claim for domestic priority under 35 U.S.C. § 119(e).

Attachment(s)

- 15) Notice of References Cited (PTO-892) 18) Interview Summary (PTO-413) Paper No(s). _____
- 16) Notice of Draftsperson's Patent Drawing Review (PTO-948) 19) Notice of Informal Patent Application (PTO-152)
- 17) Information Disclosure Statement(s) (PTO-1449) Paper No(s) 2 and 3 20) Other: _____

Art Unit: :1615

DETAILED ACTION

1. Applicant's election of Group I in Paper No. 5 and the species in claims 13-25 during subsequent telephone conversation with Alan Towner is acknowledged. Because applicant did not distinctly and specifically point out the supposed errors in the restriction requirement, the election has been treated as an election without traverse (MPEP § 818.03(a)).

Upon consideration however, the species election requirement is withdrawn. Claims 26-32 are withdrawn from consideration.

Claim Rejections - 35 USC § 103

2. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

3. Claims 1-25 are rejected under 35 U.S.C. 103(a) as being unpatentable over Duckett et al (6007,824) of record in combination with Hechtman (5,595,753) by itself or in further combination with Wyson (6,031,002).

Duckett et al disclose compositions containing L-arginine and ginseng (antioxidant) for the treatment female sexual dysfunction. Duckett et al teach that the sexual stimulation causes local release of NO resulting in the smooth muscle relaxation and the increased

Art Unit: :1615

blood flow. They further teach that L-arginine releases NO resulting in smooth muscle relaxation and increased inflow of blood (note the abstract, col. 1, line 12 through col. 2, line 46, col. 3, line 65 through col. 4, line 50 and claims). The mode of administration in Duckett however, is oral and not topical.

Hechtman while disclosing formulations containing L-arginine for treating hemorrhoidal pain and sphincter and smooth muscle spasm teaches that the formulation is applied topically (note the abstract, columns 4-5 and claims). Hechtman further discloses the relationship between NO concentrations and the smooth muscle relaxation (note col. 1, line 56 through col. 2, line 27). According to Hechtman, a constitutive NO synthase enzyme is present in smooth muscle cells and that it is likely that L-arginine directly activates the system to cause the production of NO or related compound since the sphincter relaxation occurs within 10 minutes of application of this agonist (note col. 3, line 61 through col. 4, line 7).

Wysor while disclosing prostaglandin (vasodilator) formulations for enhancing female sexual response teaches that the formulations can be applied topically to the genitals and such a topical treatment is highly effective. Wysor further teaches the use of liposome formulations for the delivery of the composition (note the abstract, columns 1-3 and claims).

The application of L-arginine containing composition of Duckett topically would have been obvious to one of ordinary skill in the art since Hechtman teaches that the L-

Art Unit: :1615

arginine is effective even when applied topically in the production of NO in smooth muscle cells. One of ordinary skill in the art would be motivated further to use Duckett's compositions topically since Wyser topical treatment for sexual dysfunction is highly effective.

4. **Claims 13-25 are rejected under 35 U.S.C. 103(a) as being unpatentable over Duckett et al (6007,824) of record in combination with Hechtman (5,595,753) by itself or in further combination with Wyson (6,031,002) as set forth above, further in view of Chobanian et al (6,139,847).**

The teachings of Duckett, Hechtman and Wyson have been discussed above. What is lacking in these references is the explicit teachings of the inclusion of an antioxidant. Although Duckett teaches the inclusion of ginseng, he neither teaches explicitly teach that this an antioxidant nor the inclusion of other antioxidants.

Chobanian et al while disclosing a treatment of fibrosis teach that antioxidants such as ascorbate, tocopherol and beta-carotene are NO catabolism inhibitors and advocates the use of the combination of NO stimulators (L-arginine) and NO catabolism inhibitors (note the abstract, col. 3, line 6 through col. 4, line 67, col. 5, line 40, Example 1 and claims).

The inclusion of an antioxidant in the compositions of Duckett would have been obvious to one of ordinary skill in the art, with the expectation of obtaining at least an additive effect, since Chobanian teaches that antioxidants are NO catabolism inhibitors and that they could be used in combination with NO stimulators.

Art Unit: :1615

The Derwent abstract (1996) which teaches that ginseng is an antioxidant is cited of interest.

5. Any inquiry concerning this communication or earlier communications from the examiner should be directed to *G.S. Kishore* whose telephone number is (703) 308-2440.

The examiner can normally be reached on Monday-Thursday from 6:30 A.M. to 4:00 P.M. The examiner can also be reached on alternate Fridays.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, T.K. Page, can be reached on (703)308-2927. The fax phone number for this Group is (703)305-3592.

Communications via Internet e-mail regarding this application, other than those under 35 U.S.C. 132 or which otherwise require a signature, may be used by the applicant and should be addressed to [thurman.page@uspto.gov].

All Internet e-mail communications will be made of record in the application file. PTO employees do not engage in Internet communications where there exists a possibility that sensitive information could be identified or exchanged unless the record includes a properly signed express waiver of the confidentiality requirements of 35 U.S.C. 122. This is more clearly set forth in the Interim Internet Usage Policy published in the Official Gazette of the Patent and Trademark on February 25, 1997 at 1195 OG 89.

Art Unit: :1615

**Any inquiry of a general nature or relating to the status of this application should
be directed to the Group receptionist whose telephone number is (703)308-1235.**



Gollamudi S. Kishore, Ph. D

Primary Examiner

Group 1600

gsk

December 10, 2001